<?xml version="1.0" encoding="utf-8"?>
<TEI xmlns="http://www.tei-c.org/ns/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:hal="http://hal.archives-ouvertes.fr/" xmlns:gml="http://www.opengis.net/gml/3.3/" xmlns:gmlce="http://www.opengis.net/gml/3.3/ce" version="1.1" xsi:schemaLocation="http://www.tei-c.org/ns/1.0 http://api.archives-ouvertes.fr/documents/aofr-sword.xsd">
  <teiHeader>
    <fileDesc>
      <titleStmt>
        <title>HAL TEI export of hal-04305428</title>
      </titleStmt>
      <publicationStmt>
        <distributor>CCSD</distributor>
        <availability status="restricted">
          <licence target="https://creativecommons.org/publicdomain/zero/1.0/">CC0 1.0 - Universal</licence>
        </availability>
        <date when="2026-05-07T19:45:09+02:00"/>
      </publicationStmt>
      <sourceDesc>
        <p part="N">HAL API Platform</p>
      </sourceDesc>
    </fileDesc>
  </teiHeader>
  <text>
    <body>
      <listBibl>
        <biblFull>
          <titleStmt>
            <title xml:lang="en">Parametric modeling study of intracellular radionuclide distribution impact in Targeted Alpha Therapy</title>
            <author role="aut">
              <persName>
                <forename type="first">Victor</forename>
                <surname>Levrague</surname>
              </persName>
              <email type="md5">5935da900a4f7a7923d9a99a7daf1c97</email>
              <email type="domain">lpsc.in2p3.fr</email>
              <idno type="idhal" notation="numeric">1534795</idno>
              <idno type="halauthorid" notation="string">2967733-1534795</idno>
              <idno type="IDREF">https://www.idref.fr/283434228</idno>
              <affiliation ref="#struct-1043144"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Mario</forename>
                <surname>Alcocer-Ávila</surname>
              </persName>
              <idno type="halauthorid">2967734-0</idno>
              <affiliation ref="#struct-572233"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Sarah</forename>
                <surname>Otmani</surname>
              </persName>
              <idno type="halauthorid">2967735-0</idno>
              <affiliation ref="#struct-1043144"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Lydia</forename>
                <surname>Maigne</surname>
              </persName>
              <idno type="halauthorid">10232-0</idno>
              <affiliation ref="#struct-1063689"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Michael</forename>
                <surname>Beuve</surname>
              </persName>
              <idno type="halauthorid">319634-0</idno>
              <affiliation ref="#struct-572233"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Etienne</forename>
                <surname>Testa</surname>
              </persName>
              <idno type="halauthorid">316486-0</idno>
              <affiliation ref="#struct-572233"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">R.</forename>
                <surname>Delorme</surname>
              </persName>
              <email type="md5">2554896804f4aec0ab4480370d545de2</email>
              <email type="domain">lpsc.in2p3.fr</email>
              <idno type="idhal" notation="string">rachel-delorme</idno>
              <idno type="idhal" notation="numeric">178709</idno>
              <idno type="halauthorid" notation="string">5990-178709</idno>
              <idno type="ORCID">https://orcid.org/0000-0003-3892-3532</idno>
              <idno type="IDREF">https://www.idref.fr/168622807</idno>
              <affiliation ref="#struct-1043144"/>
            </author>
            <editor role="depositor">
              <persName>
                <forename>Rachel</forename>
                <surname>Delorme</surname>
              </persName>
              <email type="md5">2554896804f4aec0ab4480370d545de2</email>
              <email type="domain">lpsc.in2p3.fr</email>
            </editor>
            <funder>Financial support from ITMO Cancer AVIESAN (Alliance Nationale pour les Sciences de la Vie et de la Santé/ National Alliance for Life Sciences &amp; Health) within the framework of Cancer 2020.</funder>
          </titleStmt>
          <editionStmt>
            <edition n="v1" type="current">
              <date type="whenSubmitted">2023-11-24 15:03:08</date>
              <date type="whenModified">2026-05-07 18:36:01</date>
              <date type="whenReleased">2023-11-29 07:51:34</date>
              <date type="whenProduced">2023-11-09</date>
              <ref type="annex" n="0" target="https://hal.science/hal-04305428v1/file/Abstract_EFOMP_2023_RDelorme_RIV-alpha.pdf" id="file-4305428-3761066">
                <date notBefore="2023-11-24"/>
              </ref>
            </edition>
            <respStmt>
              <resp>contributor</resp>
              <name key="736183">
                <persName>
                  <forename>Rachel</forename>
                  <surname>Delorme</surname>
                </persName>
                <email type="md5">2554896804f4aec0ab4480370d545de2</email>
                <email type="domain">lpsc.in2p3.fr</email>
              </name>
            </respStmt>
          </editionStmt>
          <publicationStmt>
            <distributor>CCSD</distributor>
            <idno type="halId">hal-04305428</idno>
            <idno type="halUri">https://hal.science/hal-04305428</idno>
            <idno type="halBibtex">levrague:hal-04305428</idno>
            <idno type="halRefHtml">&lt;i&gt;Symposium on Molecular Radiotherapy Dosimetry: The future of theragnostics&lt;/i&gt;, EFOMP, Nov 2023, Athènes, Grèce, Greece</idno>
            <idno type="halRef">Symposium on Molecular Radiotherapy Dosimetry: The future of theragnostics, EFOMP, Nov 2023, Athènes, Grèce, Greece</idno>
            <availability status="restricted">
              <licence target="https://about.hal.science/hal-authorisation-v1/">HAL Authorization<ref corresp="#file-4305428-3761066"/></licence>
            </availability>
          </publicationStmt>
          <seriesStmt>
            <idno type="stamp" n="IN2P3">Institut National de Physique Nucléaire et de Physique des Particules</idno>
            <idno type="stamp" n="UGA">HAL Grenoble Alpes</idno>
            <idno type="stamp" n="PRES_CLERMONT">Université de Clermont</idno>
            <idno type="stamp" n="LPC-CLERMONT" corresp="PRES_CLERMONT">Laboratoire de Physique Corpusculaire de Clermont-Ferrand</idno>
            <idno type="stamp" n="LPSC">Laboratoire de Physique Subatomique et de Cosmologie</idno>
            <idno type="stamp" n="CNRS">CNRS - Centre national de la recherche scientifique</idno>
            <idno type="stamp" n="UNIV-LYON1">Université Claude Bernard - Lyon I</idno>
            <idno type="stamp" n="INPG">Institut polytechnique de Grenoble</idno>
            <idno type="stamp" n="IP2I" corresp="UNIV-LYON1">Institut de Physique des 2 Infinis de Lyon</idno>
            <idno type="stamp" n="UDL">UDL</idno>
            <idno type="stamp" n="UNIV-LYON">Université de Lyon</idno>
            <idno type="stamp" n="PHABIO" corresp="IP2I">PRISME_PHABIO</idno>
            <idno type="stamp" n="UGA-EPE">Université Grenoble Alpes [2020-*]</idno>
            <idno type="stamp" n="TEST-UGA">TEST-UGA</idno>
          </seriesStmt>
          <notesStmt>
            <note type="audience" n="2">International</note>
            <note type="invited" n="0">No</note>
            <note type="popular" n="0">No</note>
            <note type="peer" n="0">No</note>
            <note type="proceedings" n="0">No</note>
          </notesStmt>
          <sourceDesc>
            <biblStruct>
              <analytic>
                <title xml:lang="en">Parametric modeling study of intracellular radionuclide distribution impact in Targeted Alpha Therapy</title>
                <author role="aut">
                  <persName>
                    <forename type="first">Victor</forename>
                    <surname>Levrague</surname>
                  </persName>
                  <email type="md5">5935da900a4f7a7923d9a99a7daf1c97</email>
                  <email type="domain">lpsc.in2p3.fr</email>
                  <idno type="idhal" notation="numeric">1534795</idno>
                  <idno type="halauthorid" notation="string">2967733-1534795</idno>
                  <idno type="IDREF">https://www.idref.fr/283434228</idno>
                  <affiliation ref="#struct-1043144"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Mario</forename>
                    <surname>Alcocer-Ávila</surname>
                  </persName>
                  <idno type="halauthorid">2967734-0</idno>
                  <affiliation ref="#struct-572233"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Sarah</forename>
                    <surname>Otmani</surname>
                  </persName>
                  <idno type="halauthorid">2967735-0</idno>
                  <affiliation ref="#struct-1043144"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Lydia</forename>
                    <surname>Maigne</surname>
                  </persName>
                  <idno type="halauthorid">10232-0</idno>
                  <affiliation ref="#struct-1063689"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Michael</forename>
                    <surname>Beuve</surname>
                  </persName>
                  <idno type="halauthorid">319634-0</idno>
                  <affiliation ref="#struct-572233"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Etienne</forename>
                    <surname>Testa</surname>
                  </persName>
                  <idno type="halauthorid">316486-0</idno>
                  <affiliation ref="#struct-572233"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">R.</forename>
                    <surname>Delorme</surname>
                  </persName>
                  <email type="md5">2554896804f4aec0ab4480370d545de2</email>
                  <email type="domain">lpsc.in2p3.fr</email>
                  <idno type="idhal" notation="string">rachel-delorme</idno>
                  <idno type="idhal" notation="numeric">178709</idno>
                  <idno type="halauthorid" notation="string">5990-178709</idno>
                  <idno type="ORCID">https://orcid.org/0000-0003-3892-3532</idno>
                  <idno type="IDREF">https://www.idref.fr/168622807</idno>
                  <affiliation ref="#struct-1043144"/>
                </author>
              </analytic>
              <monogr>
                <meeting>
                  <title>Symposium on Molecular Radiotherapy Dosimetry: The future of theragnostics</title>
                  <date type="start">2023-11-09</date>
                  <date type="end">2023-11-11</date>
                  <settlement>Athènes, Grèce</settlement>
                  <country key="GR">Greece</country>
                </meeting>
                <respStmt>
                  <resp>conferenceOrganizer</resp>
                  <name>EFOMP</name>
                </respStmt>
                <imprint/>
              </monogr>
              <ref type="publisher">https://smrd2023.efomp.org/</ref>
            </biblStruct>
          </sourceDesc>
          <profileDesc>
            <langUsage>
              <language ident="en">English</language>
            </langUsage>
            <textClass>
              <classCode scheme="halDomain" n="phys">Physics [physics]</classCode>
              <classCode scheme="halDomain" n="phys.phys.phys-bio-ph">Physics [physics]/Physics [physics]/Biological Physics [physics.bio-ph]</classCode>
              <classCode scheme="halDomain" n="phys.phys.phys-med-ph">Physics [physics]/Physics [physics]/Medical Physics [physics.med-ph]</classCode>
              <classCode scheme="halTypology" n="COMM">Conference papers</classCode>
              <classCode scheme="halOldTypology" n="COMM">Conference papers</classCode>
              <classCode scheme="halTreeTypology" n="COMM">Conference papers</classCode>
            </textClass>
            <abstract xml:lang="en">
              <p>In the context of predicting biological effects in Targeted Alpha Therapy (TAT), nano/micro-dosimetry are essential to consider the very heterogeneous dose deposition at cell level. The objective of this study is to evaluate theoretically the importance of radionuclide cell internalization in microtumors treated with TAT on physical and biological endpoints. We used Monte Carlo simulations to track alpha particles in complex in silico 3D cell populations using the CPOP/Geant4 code [1], which allows deformable cell membrane to mimic tissue compaction. The code was adapted to generate radionuclide source distributions in various internalization cases that may be encountered in targeted therapy [2] and collect specific energies, alpha kinetic energies and cross-fire contribution in each cell nucleus. The biophysical model NanOx (Nanodosimetry and Oxidative stress) [3] was used to calculate therapeutic indexes from the simulation such as Tumor Control Probability (TCP). We also studied the influence of the cell packing, tumor size, cell line, alpha’s energy and 211At radionuclide daughter diffusion after fixation. When regarding the specific energies, a low impact of radionuclide internalization was found, of less than 5% and 30% in cytoplasm and nucleus source distribution, respectively, compared to membrane adsorption only. The maximum was obtained for small tumors (30 µm radius) because of lower cross-fire contribution. The TCP calculations highlighted larger impact of radionuclide distribution for activity per cell below 30 mBq. For example, a factor up to 18 on TCP was obtained from membrane-to-nucleus distribution in a microtumor of 95µm radius treated with 211At. An RBEµ of 6.9 was calculated in the membrane distribution case. This study highlights the need for considering biological endpoints in the evaluation of intracellular radionuclide distribution impact in TAT response.[1] Maigne, L., et al. Physica Medica 89 (2021): 41-50[2] Bavelaar, B. M, et al., Frontiers in pharmacology 9 (2018): 996[3] Cunha, M., et al. Physics in Medicine &amp;amp; Biology 62.4 (2017): 1248</p>
            </abstract>
          </profileDesc>
        </biblFull>
      </listBibl>
    </body>
    <back>
      <listOrg type="structures">
        <org type="laboratory" xml:id="struct-1043144" status="VALID">
          <idno type="IdRef">184700590</idno>
          <idno type="RNSR">198512095S</idno>
          <idno type="ROR">https://ror.org/03f0apy98</idno>
          <orgName>Laboratoire de Physique Subatomique et de Cosmologie</orgName>
          <orgName type="acronym">LPSC</orgName>
          <date type="start">2020-01-01</date>
          <desc>
            <address>
              <addrLine>53 avenue des Martyrs - 38026 Grenoble Cedex</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://lpsc.in2p3.fr</ref>
          </desc>
          <listRelation>
            <relation active="#struct-300046" type="direct"/>
            <relation name="UMR5821" active="#struct-441569" type="direct"/>
            <relation active="#struct-1042703" type="direct"/>
            <relation active="#struct-1043329" type="direct"/>
          </listRelation>
        </org>
        <org type="laboratory" xml:id="struct-572233" status="VALID">
          <idno type="IdRef">24144117X</idno>
          <idno type="RNSR">199512096Z</idno>
          <idno type="ROR">https://ror.org/02avf8f85</idno>
          <orgName>Institut de Physique des 2 Infinis de Lyon</orgName>
          <orgName type="acronym">IP2I Lyon</orgName>
          <date type="start">2019-07-01</date>
          <desc>
            <address>
              <addrLine>Campus LyonTech-la DouaBâtiment Paul DIRAC4 Rue Enrico Fermi69622 Villeurbanne Cedex</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.ip2i.in2p3.fr/</ref>
          </desc>
          <listRelation>
            <relation active="#struct-194495" type="direct"/>
            <relation active="#struct-301088" type="indirect"/>
            <relation active="#struct-300046" type="direct"/>
            <relation name="UMR5822" active="#struct-441569" type="direct"/>
          </listRelation>
        </org>
        <org type="laboratory" xml:id="struct-1063689" status="VALID">
          <idno type="IdRef">224841149</idno>
          <idno type="ISNI">0000000406233622</idno>
          <idno type="RNSR">197412323M</idno>
          <idno type="ROR">https://ror.org/0214k6v65</idno>
          <orgName>Laboratoire de Physique de Clermont</orgName>
          <orgName type="acronym">LPC</orgName>
          <date type="start">2021-01-01</date>
          <desc>
            <address>
              <addrLine>Campus Universitaire des Cézeaux, 4 Avenue Blaise Pascal, TSA 60026, CS 6002, 63178 Aubière Cedex</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.lpc-clermont.in2p3.fr/</ref>
          </desc>
          <listRelation>
            <relation active="#struct-300046" type="direct"/>
            <relation name="UMR6533" active="#struct-441569" type="direct"/>
            <relation name="UMR6533" active="#struct-1063463" type="direct"/>
          </listRelation>
        </org>
        <org type="institution" xml:id="struct-300046" status="VALID">
          <idno type="IdRef">028227875</idno>
          <idno type="ISNI">0000000106643574</idno>
          <idno type="ROR">https://ror.org/03fd77x13</idno>
          <orgName>Institut National de Physique Nucléaire et de Physique des Particules du CNRS</orgName>
          <orgName type="acronym">IN2P3</orgName>
          <desc>
            <address>
              <addrLine>CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE3 rue Michel-Ange75794 PARIS CEDEX 16 - France</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">https://in2p3.cnrs.fr</ref>
          </desc>
        </org>
        <org type="regroupinstitution" xml:id="struct-441569" status="VALID">
          <idno type="IdRef">02636817X</idno>
          <idno type="ISNI">0000000122597504</idno>
          <idno type="ROR">https://ror.org/02feahw73</idno>
          <orgName>Centre National de la Recherche Scientifique</orgName>
          <orgName type="acronym">CNRS</orgName>
          <date type="start">1939-10-19</date>
          <desc>
            <address>
              <country key="FR"/>
            </address>
            <ref type="url">https://www.cnrs.fr/</ref>
          </desc>
        </org>
        <org type="regroupinstitution" xml:id="struct-1042703" status="VALID">
          <idno type="IdRef">240648315</idno>
          <idno type="ROR">https://ror.org/02rx3b187</idno>
          <orgName>Université Grenoble Alpes</orgName>
          <orgName type="acronym">UGA</orgName>
          <date type="start">2020-01-01</date>
          <desc>
            <address>
              <addrLine>Adresse CS 40700 - 38058 Grenoble cedex</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.univ-grenoble-alpes.fr</ref>
          </desc>
        </org>
        <org type="institution" xml:id="struct-1043329" status="VALID">
          <idno type="IdRef">026388804</idno>
          <idno type="ROR">https://ror.org/05sbt2524</idno>
          <orgName>Institut polytechnique de Grenoble - Grenoble Institute of Technology</orgName>
          <orgName type="acronym">Grenoble INP</orgName>
          <date type="start">2020-01-01</date>
          <desc>
            <address>
              <addrLine>46 avenue Félix Viallet 38031 Grenoble Cedex 1</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.grenoble-inp.fr/</ref>
          </desc>
          <listRelation>
            <relation active="#struct-1042703" type="direct"/>
          </listRelation>
        </org>
        <org type="institution" xml:id="struct-194495" status="VALID">
          <idno type="IdRef">026402823</idno>
          <idno type="ISNI">0000000121686185</idno>
          <idno type="ROR">https://ror.org/029brtt94</idno>
          <orgName>Université Claude Bernard Lyon 1</orgName>
          <orgName type="acronym">UCBL</orgName>
          <desc>
            <address>
              <addrLine>43, boulevard du 11 novembre 1918, 69622 Villeurbanne cedex</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.univ-lyon1.fr/</ref>
          </desc>
          <listRelation>
            <relation active="#struct-301088" type="direct"/>
          </listRelation>
        </org>
        <org type="regroupinstitution" xml:id="struct-301088" status="VALID">
          <idno type="ROR">https://ror.org/01rk35k63</idno>
          <orgName>Université de Lyon</orgName>
          <desc>
            <address>
              <addrLine>92 rue Pasteur - CS 30122, 69361 Lyon Cedex 07</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">https://www.universite-lyon.fr/</ref>
          </desc>
        </org>
        <org type="regroupinstitution" xml:id="struct-1063463" status="VALID">
          <idno type="IdRef">252404955</idno>
          <idno type="ISNI">0000000115480420</idno>
          <idno type="ROR">https://ror.org/01a8ajp46</idno>
          <orgName>Université Clermont Auvergne</orgName>
          <orgName type="acronym">UCA</orgName>
          <date type="start">2021-01-01</date>
          <desc>
            <address>
              <addrLine>49, bd François-Mitterrand / CS 60032 / 63001 Clermont-Ferrand Cedex 1</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.uca.fr/</ref>
          </desc>
        </org>
      </listOrg>
    </back>
  </text>
</TEI>